The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.

ABSTRACT:

Background

Emerging studies have shown the potential benefit of arming oncolytic viruses with therapeutic genes. However, most of these therapeutic genes are placed under the regulation of ubiquitous viral promoters. Our goal is to generate a safer yet potent oncolytic herpes simplex virus type-1 (HSV-1) for cancer therapy.

Methods

Using bacterial artificial chromosome (BAC) recombineering, a cell cycle-regulatable luciferase transgene cassette was replaced with the infected cell protein 6 (ICP6) coding region (encoded for UL39 or large subunit of ribonucleotide reductase) of the HSV-1 genome. These recombinant viruses, YE-PC8, were further tested for its proliferation-dependent luciferase gene expression.

Results

The ability of YE-PC8 to confer proliferation-dependen

SUBMITTER: Miao L 

PROVIDER: S-EPMC3887293 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature